2 articles · Bizplezx
Centralized executive decision-making in 2026 creates structural vulnerabilities for multinational firms facing regulatory divergence, talent flight, and operational silos.
Pharmaceutical firms face structural margin compression in 2026 as patent cliffs, biosimilar competition, and regulatory cost surges reshape long-term business viability across regions.